Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA3 | P07451 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 3/20 | 0.59 |
| ▸ | CA6 | P23280 | 3/20 | 0.59 |
| ▸ | CA5A | P35218 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 3/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31708315 | 1.00 | CA12 (0.59) | CA12CA1CA2CA3CA4 | |
| SCHEMBL68395 | 0.82 | HCAR2 (0.81) | CA12CA1CA2CA3CA4 | |
| SCHEMBL713717 | 0.82 | HCAR2 (0.81) | CA12CA1CA2CA3CA4 | |
| SCHEMBL14081549 | 0.82 | HCAR2 (0.81) | CA12CA1CA2CA3CA4 | |
| SCHEMBL27497699 | 0.82 | APP (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14188101 | 0.82 | HDAC8 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7746671 | 0.82 | ALDH1A1 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL7746675 | 0.82 | ALDH1A1 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL7017618 | 0.81 | MAPT (0.65) | ESR1ESR2HDAC3HDAC4HDAC1 | |
| SCHEMBL7017616 | 0.81 | MAPT (0.65) | ESR1ESR2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102637-B1 | METHOD FOR PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS OR ENGINEERED VARIANTS THEREOF USING SPECIFIC ANTHRAQUINONE DYE-LIGAND STRUCTURES | BASF SE (DE) | 2018-04-11 | — | — | EP | disclosed |
| US-20160347789-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | BASF SE (DE) | 2016-12-01 | — | — | US | disclosed |
| EP-2918641-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | BASF SE (DE) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015117984-A1 | METHOD FOR PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS OR ENGINEERED VARIANTS THEREOF USING SPECIFIC ANTHRAQUINONE DYE-LIGAND STRUCTURES | BASF SE (DE) | 2015-08-13 | — | — | WO | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| WO-2010123996-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-7534421-B2 | s-Triazine compounds bearing at least one para-aminobenzalmalonic salt substituent and photoprotective cosmetic compositions comprised thereof | L'OREAL (FR) | 2009-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347789-A1 | Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures | ANTXR2, FCGR3B, IGLV6-57 | CA12 579/4885CA1 1961/4885CA2 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.